<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197261</url>
  </required_header>
  <id_info>
    <org_study_id>OXN2503</org_study_id>
    <secondary_id>2009-018118-21</secondary_id>
    <nct_id>NCT01197261</nct_id>
  </id_info>
  <brief_title>OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)</brief_title>
  <official_title>An Exploratory, Randomised, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Assess the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets (OXN PR) Compared to Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research GmbH &amp; Co KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research GmbH &amp; Co KG</source>
  <brief_summary>
    <textblock>
      The study compares the analgesic efficacy of OXN PR vs placebo in opioid-naive subjects
      suffering from severe pain due to Bladder Pain Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening period followed by randomisation of the patients in a 1:1
      ratio to OXN PR treatment or placebo treatment in a double blind fashion. The double blind
      phase will last for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the patient's average pain during treatment with OXN PR compared with placebo</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient questionnaires</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Painful Bladder Syndrome</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>OXN PR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone Naloxone tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone naloxone prolonged release tablets</intervention_name>
    <description>2 tablets/ day</description>
    <arm_group_label>OXN PR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>2 tablets/ day</description>
    <arm_group_label>PLA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of severe pain due to Bladder Pain Syndrome (BPS) for at least 6 months

          -  Subject's treatment of pain due to BPS is insufficient

          -  Subjects must not have received opioid containing medication in the last 6 months

        Exclusion Criteria:

          -  Females who are pregnant or lactating

          -  Subjects with any contraindication/history of hypersensitivity to oxycodone, naloxone,
             paracetamol, related products or other ingredients

          -  Subjects with any situation in which opioids are contraindicated like severe
             respiratory depression with hypoxia and/or hypercapnia, severe chronic obstructive
             lung disease, cor pulmonale, severe bronchial asthma or paralytic ileus

          -  Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or
             psychiatric disease, as determined by medical history, clinical laboratory tests, ECG
             results, and physical examination that would place the subject at risk upon exposure
             to the study medication or that may confound the analysis and/or interpretation of the
             study results

          -  Abnormal aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatise
             levels (&gt; 3 times the upper limit of normal), gamma glutamyl transpeptidase &gt; 3 times
             the upper limit of normal

          -  Abnormal total bilirubin and/or creatinine level(s)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe pain</keyword>
  <keyword>Bladder Pain Syndrome</keyword>
  <keyword>Interstitial Cystitis</keyword>
  <keyword>Painful Bladder Syndrome</keyword>
  <keyword>Severe pain due to Bladder Pain Syndrome/Interstitial Cystitis/Painful Bladder Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

